A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of gaucher disease

JIMD Reports

Volumn 3, Issue , 2012, Pages 53-57

  Machaczka, Maciej ^a   Arce, Martin Paucar ^a,c   Rucinska, Malgorzata ^b   Yoshitake, Takashi ^c   Kehr, Jan ^c   Jurczak, Wojciech ^b   Skotnicki, Aleksander B ^b   Månsson, Jan Erik ^d   Tylki Szymanska, Anna ^e   Svenningsson, Per ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Gaucher disease; Glucocerebrosidase; Movement disorders; Parkinson s disease; Synucleinopathies

Indexed keywords

EID: 84872617581     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2011_48     Document Type: Chapter

References (18)

1. Alonso-Canovas A, Katschnig P, Tucci A et al (2010) Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: case report and literature review. Mov Disord 25:1506–1509
2. Bras J, Singleton A, Cookson MR, Hardy J (2008) Emerging pathways in genetic Parkinson’s disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 275:5767–5773
3. Bultron G, Kacena K, Pearson D et al (2010) The risk of Parkinson’s disease in type 1 Gaucher disease. J Inherit Metab Dis 33 (2):167–173
4. Eller M, Williams DR (2009) Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 5:561–570
5. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E (2010) Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120:641–649
6. Goldin E (2010) Gaucher disease and parkinsonism, a molecular link theory. Mol Genet Metab 101:307–310
7. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29:567–583
8. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W (1999) Parkinson’s syndrome preceding clinical manifestation of Gaucher’s disease. Am J Hematol 61:216–217
9. Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393
10. Mattsson N, Zetterberg H, Bianconi S et al (2011) Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology 76:366–372
11. Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89:691–694
12. Neumann J, Bras J, Deas E et al (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132:1783–1794
13. Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661
14. Sobstyl M, Zabek M, Koziara H, Dzierzecki S (2009) A patient with parkinsonism related to Gaucher’s disease type I successfully treated by unilateral pallidotomy – a 3-year follow-up. Neurol Neurochir Pol 43:293–297
15. Tayebi N, Walker J, Stubblefield B et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104–109
16. Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ (2006) Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66:415–417
17. Velayati A, Yu WH, Sidransky E (2010) The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 10:190–198
18. Weikop P, Yoshitake T, Kehr J (2007) Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur Neuropsychopharmacol 17:658–671